PMID- 26223814
OWN - NLM
STAT- MEDLINE
DCOM- 20160505
LR  - 20171116
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 153
IP  - 1
DP  - 2015 Aug
TI  - Assessment of HER2 status in invasive breast cancers with increased centromere 17 
      copy number.
PG  - 67-77
LID - 10.1007/s10549-015-3522-0 [doi]
AB  - This study was designed to evaluate usefulness of additional fluorescence in situ 
      hybridization (FISH) using other reference genes on chromosome 17 for assessment 
      of HER2 status in invasive breast cancers with increased centromere 17 copy 
      number, and to compare this approach with conventional methods based on the 2007 
      and 2013 ASCO/CAP guidelines. We performed FISH with probes for SMS, RARA, and 
      TP53 on 253 breast cancers with centromeric probe CEP17 copy number >/= 2.6 using 
      tissue microarrays. If one or more gene had a mean copy number <2.6, the largest 
      number for that gene(s) was chosen as an alternative to CEP17 copy number. Of the 
      243 cases in which re-grading was possible, only 2 had copy numbers >/= 2.6 for 
      RARA, SMS, and TP53. Of the 151 breast cancers which were considered HER2 
      non-amplified by the 2007 ASCO/CAP guidelines using the HER2:CEP17 ratio, 42 
      (27.8%) were re-graded as amplified and 33 (21.8%) as equivocal after FISH using 
      additional reference genes. Of the 101 HER2-non-amplified cases by the 2013 
      ASCO/CAP guidelines, 2 (2.0%) were reclassified as amplified and 24 (23.8%) as 
      equivocal. Of 46 equivocal cases, 35 (76.1%) were re-graded as amplified. After 
      re-grading, HER2-amplified cases were significantly increased, and the 
      concordance between HER2 FISH and HER2 immunohistochemistry decreased. And some 
      pathologic features of the cases which were designated to have HER2 amplification 
      after additional FISH were not compatible with those of HER2-amplified breast 
      cancers. The use of additional reference genes has been suggested as an option 
      for accurate assessment of HER2 status in breast cancers with increased CEP17 
      copy number. However, this has limitations in that it can cause over-grading of 
      HER2 status in tumors that lose the new reference genes. Thus, at present, it 
      seems that additional FISH using other reference gene such as SMS, RARA, and TP53 
      for the cases with increased CEP17 copy number is not suitable for daily 
      practice.
FAU - Jang, Min Hye
AU  - Jang MH
AD  - Department of Pathology, Seoul National University Bundang Hospital, 300 
      Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi, 463-707, Korea.
FAU - Kim, Eun Joo
AU  - Kim EJ
FAU - Kim, Hyun Jeong
AU  - Kim HJ
FAU - Chung, Yul Ri
AU  - Chung YR
FAU - Park, So Yeon
AU  - Park SY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150730
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Autoantigens)
RN  - 0 (Centromere Protein A)
RN  - 0 (Chromosomal Proteins, Non-Histone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Autoantigens/*genetics
MH  - Breast Neoplasms/*genetics/*pathology
MH  - Centromere Protein A
MH  - Chromosomal Proteins, Non-Histone/*genetics
MH  - Comparative Genomic Hybridization
MH  - *DNA Copy Number Variations
MH  - Female
MH  - Gene Amplification
MH  - Gene Deletion
MH  - *Gene Dosage
MH  - Genotype
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Neoplasm Grading
MH  - Neoplasm Invasiveness
MH  - Receptor, ErbB-2/*genetics/metabolism
EDAT- 2015/08/01 06:00
MHDA- 2016/05/06 06:00
CRDT- 2015/07/31 06:00
PHST- 2014/12/29 00:00 [received]
PHST- 2015/07/23 00:00 [accepted]
PHST- 2015/07/31 06:00 [entrez]
PHST- 2015/08/01 06:00 [pubmed]
PHST- 2016/05/06 06:00 [medline]
AID - 10.1007/s10549-015-3522-0 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2015 Aug;153(1):67-77. doi: 10.1007/s10549-015-3522-0. 
      Epub 2015 Jul 30.